Connection

BRIAN GILBERT to Sigmodontinae

This is a "connection" page, showing publications BRIAN GILBERT has written about Sigmodontinae.
Connection Strength

0.591
  1. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
    View in: PubMed
    Score: 0.143
  2. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7.
    View in: PubMed
    Score: 0.104
  3. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
    View in: PubMed
    Score: 0.096
  4. In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections. Virology. 2023 09; 586:115-121.
    View in: PubMed
    Score: 0.049
  5. A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun. 2016 12 21; 7:13916.
    View in: PubMed
    Score: 0.031
  6. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
    View in: PubMed
    Score: 0.031
  7. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
    View in: PubMed
    Score: 0.029
  8. Benzimidazole analogs inhibit respiratory syncytial virus G protein function. Antiviral Res. 2015 Sep; 121:31-8.
    View in: PubMed
    Score: 0.028
  9. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. 2014 Nov; 6(11):1436-54.
    View in: PubMed
    Score: 0.027
  10. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol. 2014 May; 88(9):5100-8.
    View in: PubMed
    Score: 0.026
  11. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005 Oct; 68(1):18-26.
    View in: PubMed
    Score: 0.014
  12. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 2003 Nov; 60(3):221-31.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.